DMRA

Damora Therapeutics, Inc. Ordinary Shares

23.70

USD

+1.84

+8.42%

Nov 06, 15:59 UTC -5

Closed

After-Market

23.70

0.00

+0.02%

Damora Therapeutics, Inc. Ordinary Shares (DMRA) Earnings

DMRA Earnings Reports

Positive Surprise Ratio

DMRA beat 2 of 3 last estimates.

67%

Next Report

Date of Next Report

Mar 17, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.52

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-119.26%

Damora Therapeutics, Inc. Ordinary Shares earnings per share and revenue

On Oct 30, 2026, DMRA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.49 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.52 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

FAQ

What were Damora Therapeutics, Inc. Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Damora Therapeutics, Inc. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.

How did the market react to Damora Therapeutics, Inc. Ordinary Shares's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Damora Therapeutics, Inc. Ordinary Shares expected to report next?

The next earning report is scheduled for Mar 17, 2027.

What are the forecasts for Damora Therapeutics, Inc. Ordinary Shares's next earnings report?

Based on -- analysts, Damora Therapeutics, Inc. Ordinary Shares is expected to report EPS of -$0.52 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.